[go: up one dir, main page]

SG11202004662RA - Anti-c5 antibody combinations and uses thereof - Google Patents

Anti-c5 antibody combinations and uses thereof

Info

Publication number
SG11202004662RA
SG11202004662RA SG11202004662RA SG11202004662RA SG11202004662RA SG 11202004662R A SG11202004662R A SG 11202004662RA SG 11202004662R A SG11202004662R A SG 11202004662RA SG 11202004662R A SG11202004662R A SG 11202004662RA SG 11202004662R A SG11202004662R A SG 11202004662RA
Authority
SG
Singapore
Prior art keywords
antibody combinations
antibody
combinations
Prior art date
Application number
SG11202004662RA
Inventor
Kishor Devalaraja-Narashimha
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202004662RA publication Critical patent/SG11202004662RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
SG11202004662RA 2017-12-13 2018-12-12 Anti-c5 antibody combinations and uses thereof SG11202004662RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762598023P 2017-12-13 2017-12-13
PCT/US2018/065123 WO2019118556A1 (en) 2017-12-13 2018-12-12 Anti-c5 antibody combinations and uses thereof

Publications (1)

Publication Number Publication Date
SG11202004662RA true SG11202004662RA (en) 2020-06-29

Family

ID=65139108

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004662RA SG11202004662RA (en) 2017-12-13 2018-12-12 Anti-c5 antibody combinations and uses thereof

Country Status (13)

Country Link
US (3) US11365265B2 (en)
EP (1) EP3724226A1 (en)
JP (2) JP2021506241A (en)
KR (1) KR20200098528A (en)
CN (2) CN120571008A (en)
AU (2) AU2018383751B2 (en)
CA (1) CA3083113A1 (en)
IL (2) IL275264B2 (en)
MA (1) MA51147A (en)
MX (3) MX2020006113A (en)
PH (1) PH12020550825A1 (en)
SG (1) SG11202004662RA (en)
WO (1) WO2019118556A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633434B2 (en) 2016-06-14 2020-04-28 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies
KR20200070355A (en) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 Dosage and administration of anti-C5 antibodies for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS)
CN120571008A (en) 2017-12-13 2025-09-02 瑞泽恩制药公司 Anti-C5 antibody combinations and uses thereof
TWI866924B (en) * 2018-08-30 2024-12-21 美商再生元醫藥公司 Methods for characterizing protein complexes
WO2021034639A1 (en) * 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. High concentration anti-c5 formulations
US20240018220A1 (en) * 2020-10-23 2024-01-18 Alexion Pharmaceuticals, Inc. Methods of treating patients having complement disorders using anti-c5 antibodies
WO2022155340A1 (en) * 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
KR20230105972A (en) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 ANTI-C3b ANTIBODY OR ANTI-C5 ANTIBODY CONJUGATED WITH ANGIOGENESIS INHIBITOR AND USE THEREOF

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
EP0591462B1 (en) 1991-07-15 2003-04-16 Oklahoma Medical Research Foundation Universal donor cells
AU4657993A (en) 1992-06-29 1994-01-24 Alexion Pharmaceuticals, Inc. Matrix for universal donor microvascular endothelial cells
CA2186108A1 (en) 1994-03-23 1995-09-28 Scott A. Rollins Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5562904A (en) 1994-07-21 1996-10-08 Alexion Pharmaceuticals, Inc. Retroviral transduction of cells using soluble complement inhibitors
DE69534701T2 (en) 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire METHOD FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
ES2483991T3 (en) 2000-10-10 2014-08-08 Genentech, Inc. Antibodies against C5 that inhibits the activation of type II endothelial cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
BRPI0211953B8 (en) 2001-08-17 2021-05-25 Genentech Inc monoclonal antibody or antigen-binding fragment that binds to c5 and c5a without the prevention of c5b formation, cell lineage, pharmaceutical composition, as well as in vitro method to inhibit c5a activity and in vitro diagnostic method
EP1878441B1 (en) 2001-08-17 2018-01-24 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
ITMI20021527A1 (en) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
WO2004022096A1 (en) 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
EP2660322A3 (en) 2003-04-17 2013-11-13 Alnylam Pharmaceuticals Inc. Modified iRNA agents
NZ544163A (en) 2003-06-02 2009-06-26 Evolutec Ltd Complement inhibitors
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
JP5848861B2 (en) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Human monoclonal antibody against CD20
SI1755674T1 (en) 2004-05-14 2015-04-30 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7763708B2 (en) 2004-08-12 2010-07-27 Institute For Protein Science Co., Ltd. Methods and compositions for modulating C5-a-mediated inflammatory responses
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US8883162B2 (en) * 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
MX337061B (en) 2005-11-04 2016-02-11 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases.
AU2013200223B2 (en) 2005-11-04 2015-08-20 Genentech, Inc. Use of Complement Pathway Inhibitors to Treat Ocular Diseases
CN101437501B (en) 2006-03-02 2012-09-05 阿莱克申药物公司 Prolonged allograft survival by inhibiting complement activity
ES2965283T3 (en) 2006-03-15 2024-05-28 Alexion Pharma Inc Treatment of patients with paroxysmal nocturnal hemoglobinuria using a complement inhibitor
MX2008014804A (en) 2006-06-02 2009-01-27 Regeneron Pharma High affinity antibodies to human il-6 receptor.
MX2009002426A (en) 2006-09-05 2009-03-20 Alexion Pharma Inc Method and compositions for the treatment of antibody mediated neuropathies.
PL2061501T3 (en) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Method of treating respiratory disorders
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
LT3028716T (en) 2006-10-10 2020-12-10 Regenesance B.V. Complement inhibition for improved nerve regeneration
PL2148691T3 (en) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
AR069130A1 (en) 2007-11-02 2009-12-30 Novartis Ag LINK MOLECULES OF THE MAIN COMPLEMENT OPSONIN (C3B) AND METHODS TO MODULATE THE COMPLEMENT COMPONENT
UA121453C2 (en) 2008-04-11 2020-06-10 Чугей Сейяку Кабусікі Кайся METHOD OF PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY
US8023425B2 (en) 2009-01-28 2011-09-20 Headwater Partners I Verifiable service billing for intermediate networking devices
AU2014201433B2 (en) 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
ES2643411T3 (en) 2008-08-05 2017-11-22 Novartis Ag Compositions and methods for antibodies directed to the complement protein C5
AU2009298684B2 (en) 2008-09-30 2015-11-19 Konstantinos Ritis Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
US9891219B2 (en) 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
CA3035432A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
JP2012531418A (en) * 2009-06-23 2012-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド Bispecific antibodies that bind complement proteins
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CA2768463A1 (en) 2009-07-17 2011-01-20 Corning Cable Systems Llc Optical fiber ribbons and ribbon matrix materials having low oligomer content
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP2521562B1 (en) 2010-01-08 2019-09-18 Volution Immuno Pharmaceuticals SA Ev576 for use in the treatment of viral infections of the respiratory tract
PL2505654T5 (en) 2010-02-08 2020-11-30 Regeneron Pharmaceuticals, Inc. Common light chain mouse
BR112012022214A2 (en) 2010-03-01 2017-07-04 Alexion Pharma Inc methods and compositions for treating degum disease
TWI667257B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
AU2015201676B2 (en) 2010-04-30 2016-10-13 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
PT2563813E (en) * 2010-04-30 2015-11-26 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
CA2833785C (en) 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
EP2854760B1 (en) 2012-05-25 2018-10-17 Novartis AG Aqueous pharmaceutical composition containing a biologic therapeutic agent and l-arginine derivative and an injection including the composition
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TW201418707A (en) 2012-09-21 2014-05-16 Alexion Pharma Inc Screening assays for complement component C5 antagonists
BR112015018438A2 (en) 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation c5 antibody and method for preventing and treating complement-related diseases
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibody containing chimeric constant region
US9701743B2 (en) 2014-02-20 2017-07-11 Allergan, Inc. Complement component C5 antibodies
CA2897334A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
US20150079613A1 (en) 2013-08-07 2015-03-19 Ryan Kitchel Atypical hemolytic uremic syndrome biomarker proteins
WO2015039126A1 (en) 2013-09-16 2015-03-19 Children hospital medical center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
EP3054965B1 (en) 2013-10-07 2021-04-14 Massachusetts Eye & Ear Infirmary Anti-factor d antibody for use in preventing or reducing retinal detachment
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US20170073754A1 (en) 2014-02-07 2017-03-16 Novartis Ag Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
KR20160124787A (en) 2014-02-21 2016-10-28 메디뮨 엘엘씨 -pcsk9glp-1 anti-pcsk9glp-1 fusions and methods for use
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CN116785426A (en) 2014-03-20 2023-09-22 因弗拉克斯有限责任公司 C5a inhibitors for the treatment of viral pneumonia
CA3225091A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US10177705B2 (en) 2014-07-12 2019-01-08 Kaneka Corporation Composite solar cell, solar cell module, and concentrating solar cell
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
EP3247723A1 (en) 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
US20190135903A1 (en) 2015-03-31 2019-05-09 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
WO2016178980A1 (en) 2015-05-01 2016-11-10 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
US20160362482A1 (en) 2015-06-10 2016-12-15 Case Western Reserve University Compositions and methods of modulating b cell response
WO2016201301A1 (en) * 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
JP2018528218A (en) 2015-09-11 2018-09-27 アンドリアン、ブルース Recombinant glycosylated eculizumab and eculizumab variants
WO2017055908A1 (en) 2015-09-28 2017-04-06 Noris Marina Methods of treating adamts13 deficiencies and congenital thrombotic thrombocytopenia in pediatric patients
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
TW201718014A (en) 2015-10-12 2017-06-01 諾華公司 Use of C5 inhibitors in Transplant Associated Microangiopathy
JP7221691B2 (en) 2015-10-30 2023-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Method for inhibiting exacerbation of T cell-mediated allograft vasculopathy
SI3390442T1 (en) 2015-12-18 2024-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
WO2017123636A1 (en) 2016-01-11 2017-07-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
WO2017132259A1 (en) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3463461A4 (en) 2016-05-27 2020-05-20 Alexion Pharmaceuticals, Inc. METHODS OF TREATING GENERALIZED REFRACTORY SEVERE MYASTHENIA
US20190225678A1 (en) 2016-06-07 2019-07-25 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
CN109310760A (en) 2016-06-07 2019-02-05 诺华股份有限公司 Anti-C5 Antibody Dosing Regimen
WO2017214518A1 (en) 2016-06-10 2017-12-14 Alnylam Pharmaceuticals, Inc. COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
US10633434B2 (en) 2016-06-14 2020-04-28 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies
TWI610941B (en) 2016-06-17 2018-01-11 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibody and method of use
US11303992B2 (en) 2016-07-06 2022-04-12 Macho Daisy, Llc. Wearable device and system for personal audio messaging
EP3512964B1 (en) 2016-09-14 2021-12-15 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of diagnosing and treating cd55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (chaple), a newly identified orphan disease
WO2018071624A1 (en) 2016-10-12 2018-04-19 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
US10802945B2 (en) 2016-12-07 2020-10-13 Ab Initio Technology Llc Differencing of executable dataflow graphs
WO2018109588A2 (en) 2016-12-16 2018-06-21 Samsung Bioepis Co., Ltd Stable aqueous anti-c5 antibody composition
CN110167961A (en) 2017-01-31 2019-08-23 中外制药株式会社 Pharmaceutical compositions for treating or preventing C5-related diseases and methods of treating or preventing C5-related diseases
BR112019018429A2 (en) 2017-03-06 2020-04-14 Univ Pennsylvania antibody, methods for treating an individual's complement-mediated disease or disorder and for reducing the activity of an individual's complement system, and, cell
MX2019011252A (en) 2017-03-23 2020-01-23 Univ Pennsylvania Anti-c5a antibodies and uses thereof.
JP2020517605A (en) 2017-04-19 2020-06-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド Efficacy of anti-C5 antibody in preventing antibody-mediated rejection in sensitized kidney transplant recipients
JP7502865B2 (en) 2017-06-23 2024-06-19 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Treatment of inflammatory diseases with inhibitors of C5A activity
CN120571008A (en) 2017-12-13 2025-09-02 瑞泽恩制药公司 Anti-C5 antibody combinations and uses thereof
WO2021034639A1 (en) 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. High concentration anti-c5 formulations

Also Published As

Publication number Publication date
US20240392039A1 (en) 2024-11-28
AU2018383751A1 (en) 2020-06-25
WO2019118556A1 (en) 2019-06-20
IL275264B2 (en) 2026-02-01
KR20200098528A (en) 2020-08-20
US12084516B2 (en) 2024-09-10
US20220275107A1 (en) 2022-09-01
AU2025213593A1 (en) 2025-08-28
JP2024020446A (en) 2024-02-14
CN120571008A (en) 2025-09-02
MX2020006113A (en) 2020-08-24
IL323440A (en) 2025-11-01
IL275264B1 (en) 2025-10-01
MX2025002470A (en) 2025-04-02
IL275264A (en) 2020-07-30
US20190177436A1 (en) 2019-06-13
MX2025002472A (en) 2025-04-02
AU2018383751B2 (en) 2025-05-08
JP2021506241A (en) 2021-02-22
CA3083113A1 (en) 2019-06-20
MA51147A (en) 2021-03-24
PH12020550825A1 (en) 2021-05-17
US11365265B2 (en) 2022-06-21
CN111630065A (en) 2020-09-04
EP3724226A1 (en) 2020-10-21

Similar Documents

Publication Publication Date Title
IL324531A (en) Anti-c5 antibodies and uses thereof
IL312910B1 (en) Anti-galectin-9 antibodies and uses thereof
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and uses thereof
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL268734A (en) Anti-lag-3 antibodies and uses thereof
IL268206A (en) Bcma-targeting antibody and use thereof
IL269134A (en) Anti-par2 antibodies and uses thereof
SG11201808632YA (en) Anti-pacap antibodies and uses thereof
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
IL273157A (en) Axl-specific antibodies and uses thereof
IL275264B2 (en) Anti-c5 antibody combinations and uses thereof
IL272476A (en) Anti-apelin antibodies and uses thereof
IL266082A (en) Anti-chikv antibodies and uses thereof
IL266049A (en) Anti-o1 antibodies and uses thereof
IL274202A (en) Anti-glyco-muc1 antibodies and their uses
IL264417A (en) Anti-o2 antibodies and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
SG11202003585VA (en) Anti-vista antibody and use thereof
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
HK40017842A (en) Anti-c5 antibodies and uses thereof